CA2840307C - Progenitor cells of mesodermal lineage - Google Patents

Progenitor cells of mesodermal lineage Download PDF

Info

Publication number
CA2840307C
CA2840307C CA2840307A CA2840307A CA2840307C CA 2840307 C CA2840307 C CA 2840307C CA 2840307 A CA2840307 A CA 2840307A CA 2840307 A CA2840307 A CA 2840307A CA 2840307 C CA2840307 C CA 2840307C
Authority
CA
Canada
Prior art keywords
progenitor cells
mesodermal lineage
mesodermal
lineage
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2840307A
Other languages
English (en)
French (fr)
Other versions
CA2840307A1 (en
Inventor
Thomas Averell HOUZE
Martin John Evans
Ajan Reginald
Ina Laura PIEPER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Therapy Ltd
Original Assignee
Cell Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1111503.7A external-priority patent/GB201111503D0/en
Priority claimed from GBGB1111500.3A external-priority patent/GB201111500D0/en
Priority claimed from GBGB1111509.4A external-priority patent/GB201111509D0/en
Priority claimed from GBGB1111505.2A external-priority patent/GB201111505D0/en
Application filed by Cell Therapy Ltd filed Critical Cell Therapy Ltd
Publication of CA2840307A1 publication Critical patent/CA2840307A1/en
Application granted granted Critical
Publication of CA2840307C publication Critical patent/CA2840307C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
CA2840307A 2011-07-06 2012-07-06 Progenitor cells of mesodermal lineage Active CA2840307C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1111500.3 2011-07-06
GBGB1111503.7A GB201111503D0 (en) 2011-07-06 2011-07-06 Heart failure (HF) MSC subtype
GBGB1111500.3A GB201111500D0 (en) 2011-07-06 2011-07-06 Wet age-related macular degeneration MSC subtype
GB1111505.2 2011-07-06
GB1111503.7 2011-07-06
GB1111509.4 2011-07-06
GBGB1111509.4A GB201111509D0 (en) 2011-07-06 2011-07-06 Orthopedic MSC subtype
GBGB1111505.2A GB201111505D0 (en) 2011-07-06 2011-07-06 MI MSC subtype
PCT/GB2012/051600 WO2013005053A2 (en) 2011-07-06 2012-07-06 Progenitor cells of mesodermal lineage

Publications (2)

Publication Number Publication Date
CA2840307A1 CA2840307A1 (en) 2013-01-10
CA2840307C true CA2840307C (en) 2021-10-19

Family

ID=46513785

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2840307A Active CA2840307C (en) 2011-07-06 2012-07-06 Progenitor cells of mesodermal lineage

Country Status (19)

Country Link
US (3) US10472609B2 (enExample)
EP (1) EP2729562B1 (enExample)
JP (2) JP6607675B2 (enExample)
CN (2) CN104508124B (enExample)
AU (2) AU2012279995C1 (enExample)
CA (1) CA2840307C (enExample)
CY (1) CY1120646T1 (enExample)
DK (1) DK2729562T3 (enExample)
EA (1) EA029577B1 (enExample)
ES (1) ES2675693T3 (enExample)
HR (1) HRP20181152T1 (enExample)
HU (1) HUE039236T2 (enExample)
IL (2) IL230071B (enExample)
LT (1) LT2729562T (enExample)
MY (1) MY185016A (enExample)
PL (1) PL2729562T3 (enExample)
PT (1) PT2729562T (enExample)
SG (1) SG10201605518XA (enExample)
WO (1) WO2013005053A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
PL2782555T3 (pl) * 2011-11-23 2019-09-30 Cell Therapy Limited Żel z lizatem płytek krwi
JP6615753B2 (ja) * 2013-10-04 2019-12-04 レジニアス リミテッド 細胞療法のためのバイオマーカー
GB201408712D0 (en) * 2014-05-16 2014-07-02 Univ Leuven Kath Mesodermal progenitor cells
GB201410504D0 (en) 2014-06-12 2014-07-30 Cell Therapy Ltd Immuno-modulaltory progenitor (IMP) cell
CN107076745A (zh) * 2014-08-29 2017-08-18 贝克顿·迪金森公司 在受试者中获得结核病评价的方法和组合物
JP2018512061A (ja) * 2015-02-20 2018-05-10 ナショナル ヤン−ミン ユニバーシティ 骨関節炎処置のための間葉幹細胞の使用
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
GB201513996D0 (en) 2015-08-07 2015-09-23 Cell Therapy Ltd Immuno-oncology mesodermal progenitor (IOMP) cell
JP6830893B2 (ja) 2015-09-11 2021-02-17 アステラス製薬株式会社 腎前駆細胞を製造する方法
GB201518263D0 (en) 2015-10-15 2015-12-02 Oxford Bioelectronics Ltd Method
CN105483206B (zh) * 2016-01-06 2019-09-13 北京汉氏联合生物技术股份有限公司 一种用vcam-1检测msc促内皮细胞增殖能力的方法
US11066648B2 (en) * 2016-08-29 2021-07-20 Hackensack University Medical Center Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
CA3033750A1 (en) * 2016-08-29 2018-03-08 Hackensack University Medical Center Compositions and methods for programming adult cells with platelet rich fraction of blood containing platelet-like cells
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
JP7009977B2 (ja) * 2017-12-25 2022-01-26 国立大学法人東海国立大学機構 被検体の血中ｖｅｇｆ－ａに関する測定値を用いた心疾患の重症度及び予後予測を行うための方法、装置及びコンピュータプログラム
CN108715833B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
US12310989B2 (en) * 2018-11-14 2025-05-27 Onderzoeks- En Ontwikkelingsfonds Rode Kruis-Vlaanderen Methods for preparing platelet releasate
CN109329270A (zh) * 2018-11-19 2019-02-15 成都清科生物科技有限公司 一种静脉回输用间充质干细胞保存液及其制备方法
GB201900554D0 (en) 2019-01-15 2019-03-06 Cell Therapy Ltd Mesodermal killer (mk) cell
US20230047325A1 (en) * 2019-01-15 2023-02-16 Cell Therapy Limited Mesodermal killer (mk) cell
WO2020157660A1 (en) * 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
EP3968992A4 (en) * 2019-05-15 2023-06-21 Stemcyte, Inc. PACKAGING AND SHIPPING HIGH CONCENTRATION CELLS
CN110237094B (zh) * 2019-07-30 2023-10-03 天晴干细胞股份有限公司 一种底层血小板因子贴及sPL血小板因子凝胶贴膜的制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
RU2138162C1 (ru) 1997-04-17 1999-09-27 Суханов Владимир Александрович Способ криоконсервации богатой тромбоцитами плазмы
EP1028737B1 (en) 1997-07-03 2007-04-04 Osiris Therapeutics, Inc. Human mesenchymal stem cells from peripheral blood
WO1999011287A1 (en) 1997-09-04 1999-03-11 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
EP1082410B1 (en) 1998-05-29 2007-08-01 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
DK1226233T3 (da) 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
AUPR703601A0 (en) 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
JP2003055237A (ja) * 2001-08-15 2003-02-26 Japan Science & Technology Corp 骨再生促進剤
DE60314602T2 (de) 2002-02-19 2008-02-28 Medipost, Co., Ltd. Verfahren zur isolierung und kulturexpansion mesenchymaler stamm-/vorläuferzellen aus nabelschnurblut sowie verfahren zur differenzierung von aus nabelschnurblut stammenden mesenchymalen stamm-/vorläuferzellen in unterschiedliche mesenchymgewebe
KR100534215B1 (ko) 2003-11-11 2005-12-08 (주)히스토스템 냉동 보관된 제대혈로부터 중간엽 줄기세포의 분리 및 배양 방법
DE102005011568A1 (de) 2004-04-13 2005-11-17 Man Roland Druckmaschinen Ag Produktionsverfahren für eine Prägeeinrichtung in einer Bogendruckmaschine
US20090047257A1 (en) 2004-07-20 2009-02-19 Case Western Reserve University Novel cell populations and uses thereof
AU2005287855B2 (en) 2004-09-24 2011-06-16 Mesoblast, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
US20080260694A1 (en) 2004-09-24 2008-10-23 Angioblast Systems, Inc. Multipotential Expanded Mesenchymal Precursor Cell Progeny (Memp) and Uses Thereof
KR101617319B1 (ko) 2005-04-12 2016-05-02 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리
KR100679642B1 (ko) * 2005-11-16 2007-02-06 주식회사 알앤엘바이오 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
ES2415855T3 (es) 2006-01-13 2013-07-29 Osiris Therapeutics, Inc. Células troncales mesenquimatosas que expresan el receptor de TNF
EP1845154A1 (en) 2006-04-12 2007-10-17 RNL Bio Co., Ltd. Multipotent stem cells derived from placenta tissue and cellular therapeutic agents comprising the same
US20100111910A1 (en) 2006-07-12 2010-05-06 Angioblast Systems, Inc. Treatment of excessive neovascularization
US20090253151A1 (en) 2006-09-01 2009-10-08 Stempeutics Research Private Limited Self-Renewing Master Adult Pluripotent Stem Cells
WO2008097828A2 (en) 2007-02-02 2008-08-14 St. Jude Children's Research Hospital Method for isolating mesenchymal stromal cells
WO2008129563A2 (en) 2007-04-23 2008-10-30 Stempeutics Research Private Limited, Human mesenchymal stem cells and preparation thereof
US20090053182A1 (en) 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
EP2014294A1 (en) 2007-07-13 2009-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of CD200 as a mesenchymal stem cells marker
WO2009044943A1 (en) 2007-10-01 2009-04-09 Seoul National University Industry Foundation Various human dental stem cells having a mineralization ability and the method for culturing them
WO2009061024A1 (en) 2007-11-09 2009-05-14 Rnl Bio Co., Ltd Method for isolating and culturing adult stem cells derived from human amniotic epithelium
CA2692765C (en) * 2007-11-30 2015-09-22 Rnl Bio Co., Ltd Cellular therapeutic agent for incontinence of urine comprising stem cells originated from decidua or adipose
EP2297305A4 (en) 2008-05-15 2013-03-13 Univ Miami ISOLATION OF STEM CELL PROCESSORS AND EXPANSION UNDER NON-TERMS OF CONDITION
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
EP2321408A4 (en) 2008-08-04 2013-04-17 Allocure Inc MESENCHYMAL STROMAZELL POPULATIONS AND PROCESS FOR THEIR INSULATION AND USE
US9090678B2 (en) 2008-08-18 2015-07-28 Mesoblast, Inc. Monoclonal antibody STRO-4
JP5793724B2 (ja) * 2008-08-22 2015-10-14 公益財団法人ヒューマンサイエンス振興財団 脳梗塞治療材
EP2334785B2 (en) 2008-09-16 2019-08-14 Mayo Foundation For Medical Education And Research Compositions containing platelet contents
EP2186883A1 (en) 2008-11-04 2010-05-19 Fresenius Medical Care An isolated multipotent mesenchymal stem cell from human adult glomeruli (hGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
KR102011609B1 (ko) 2008-11-20 2019-08-16 메소블라스트, 아이엔씨. 췌장 기능장애를 치료 또는 예방하는 방법
US20120020937A1 (en) 2009-04-28 2012-01-26 Anterogen Co., Ltd. Autologous and allogenic adipose-derived stromal stem cell composition for treating fistulas
EP2488187A4 (en) 2009-10-13 2014-03-26 Allocure Inc ASSAY FOR PREDICTING THE THERAPEUTIC EFFECT OF MECHANICAL CYCLES AND METHOD OF USE THEREOF
ES2358146B1 (es) 2009-10-22 2012-03-23 Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla Uso de células mesenquimales nestina positivas para el mantenimiento de la hematopoyesis.
US20110123498A1 (en) 2009-10-30 2011-05-26 Christof Westenfelder Mesenchymal stromal cell populations and methods of using same
CN102048756B (zh) 2009-11-04 2014-02-19 中国医学科学院基础医学研究所 人脂肪来源的间充质干细胞在肾脏、眼底疾病中的用途
WO2011068792A2 (en) 2009-12-01 2011-06-09 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
EP2506867B1 (en) * 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
KR101871472B1 (ko) 2010-07-02 2018-06-27 메소블라스트, 아이엔씨. 이식편대숙주 질환의 치료 방법
JP6061345B2 (ja) 2010-08-27 2017-01-18 ユニヴァーシティ・オヴ・マイアミ 心臓修復のための骨髄由来ｃｄ２７１前駆細胞
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
ES2384790B1 (es) 2010-12-10 2013-05-20 Instituto De Salud Carlos Iii Células madre mesenquimales aisladas a partir de sangre periférica.
US20120288480A1 (en) 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
CN102078644A (zh) * 2011-03-08 2011-06-01 吉林大学 一种简便高效的自体富血小板血浆提取装置及提取方法
SG194930A1 (en) 2011-05-19 2013-12-30 Mesoblast Inc Methods for treating obesity and/or metabolic syndrome
CN103826646A (zh) 2011-06-03 2014-05-28 麦瑟布莱斯特公司 治疗中风的影响的方法
CN109276706A (zh) 2011-06-03 2019-01-29 麦瑟布莱斯特公司 治疗或预防神经性疾病的方法
WO2013003899A1 (en) 2011-07-04 2013-01-10 Mesoblast, Inc Methods of treating or preventing rheumatic disease
CN108635377B (zh) 2011-09-09 2022-06-24 麦瑟布莱斯特公司 增加成骨细胞功能的方法
JP6348848B2 (ja) 2012-02-13 2018-06-27 ガミダ セル リミテッド 間葉系幹細胞の増殖
US20150064141A1 (en) 2012-04-05 2015-03-05 The Regents Of The University Of California Regenerative sera cells and mesenchymal stem cells
US20130273011A1 (en) 2012-04-17 2013-10-17 Medistem, Inc. Stem cells and stem cell generated nanoparticles for treatment of inflammatory conditions and acute radiation syndrome

Also Published As

Publication number Publication date
US20150071886A1 (en) 2015-03-12
CN107746830A (zh) 2018-03-02
AU2012279995A1 (en) 2014-01-23
IL264455A (en) 2019-02-28
WO2013005053A3 (en) 2013-06-13
CN104508124B (zh) 2017-11-17
CN104508124A (zh) 2015-04-08
US10472609B2 (en) 2019-11-12
HRP20181152T1 (hr) 2018-09-21
CA2840307A1 (en) 2013-01-10
EA201391773A1 (ru) 2014-11-28
AU2012279995B2 (en) 2017-03-30
JP2014520523A (ja) 2014-08-25
WO2013005053A2 (en) 2013-01-10
SG10201605518XA (en) 2016-08-30
ES2675693T3 (es) 2018-07-11
DK2729562T3 (en) 2018-07-23
MY185016A (en) 2021-04-30
AU2012279995C1 (en) 2019-10-24
AU2017204559A1 (en) 2017-07-20
EP2729562A2 (en) 2014-05-14
EA029577B1 (ru) 2018-04-30
JP2017225451A (ja) 2017-12-28
CY1120646T1 (el) 2019-12-11
US10829739B2 (en) 2020-11-10
PL2729562T3 (pl) 2018-10-31
PT2729562T (pt) 2018-07-18
NZ620283A (en) 2016-06-24
HUE039236T2 (hu) 2018-12-28
US11873513B2 (en) 2024-01-16
EP2729562B1 (en) 2018-04-18
IL230071B (en) 2019-02-28
JP6607675B2 (ja) 2019-11-20
US20210032600A1 (en) 2021-02-04
LT2729562T (lt) 2018-07-25
US20200048613A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
CA2840307C (en) Progenitor cells of mesodermal lineage
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
IN2014DN06104A (enExample)
WO2013158851A3 (en) Improving skin appearance with increase in skin chroma
CA144263S (en) Toy construction cell component
CA144264S (en) Toy construction cell component
WO2013106273A3 (en) Peptides and methods of using same
EP3299451B8 (en) Methods of using adipose tissue-derived cells in the treatment of raynaud's phenomenon
HK1256159A1 (zh) 免疫-肿瘤中胚层祖细胞(iomp)细胞
GB201222455D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
EP3087193A4 (en) Compositions and methods for providing active telomerase to cells in vivo
HK1206984A1 (en) Combination therapy of anti-mif antibodies and glucocorticoids
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
IL230751A0 (en) New peptides, preparations containing them and used in methods to treat metabolic, cardiac and immune diseases
AU346524S (en) Spacer
ZA201401941B (en) Compositions to be applied to the skin, and uses thereof
AU346989S (en) Coupling nut
WO2013079924A3 (en) Modified exonuclease
EA201792475A1 (ru) Клетки-предшественники мезодермальной линии
AU333656S (en) Seat
AU339164S (en) Bag
AU339161S (en) Bag
AU339696S (en) Shelving
AU345049S (en) Compressor
AU346933S (en) Rechargeable pepper spray canister

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170627